Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | GAA | P10253 | 10/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.43 |
| ▸ | TUBB | P07437 | 4/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290766 | 0.95 | GAA (0.48) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2287288 | 0.93 | KMT2A (0.40) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2288553 | 0.93 | MAPT (0.48) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2287237 | 0.90 | MAPT (0.48) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2290771 | 0.89 | MAPT (0.42) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2287599 | 0.88 | GAA (0.41) | MAPTGAASMN1; SMN2TP53THRB | |
| SCHEMBL2814905 | 0.88 | GAA (0.51) | MAPTGAAKMT2AMAPK1TP53 | |
| SCHEMBL2296111 | 0.87 | TRIM33 (0.38) | MAPTGAASMN1; SMN2TP53THRB | |
| SCHEMBL2292837 | 0.87 | MAPT (0.50) | MAPTGAASMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2290761 | 0.87 | MAPT (0.41) | MAPTGAASMN1; SMN2TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | claimed |
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | MAPT 1138/4885GAA 1202/4885SMN1; SMN2 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.